AAAAAA
Results:
1-21
|
Results: 21
Authors:
CREAGAN ET
VEEDER MH
SUMAN VJ
BURCH PA
MAPLES WJ
SCHAEFER PL
PFEIFLE DM
DALTON RJ
HATFIELD AK
POON MA
Citation: Et. Creagan et al., A PHASE-II STUDY OF HIGH-DOSE CIMETIDINE AND THE COMBINATION 5-FLUOROURACIL, INTERFERON ALPHA-2A, AND LEUCOVORIN IN ADVANCED RENAL-CELL ADENOCARCINOMA, American journal of clinical oncology, 21(5), 1998, pp. 475-478
Authors:
CREAGAN ET
HESTORRF RD
SUMAN VJ
MAILLIARD JA
NAIR S
KROOK JE
KUGLER JW
MARSCHKE RF
MICHALAK JC
TSCHETTER LK
Citation: Et. Creagan et al., COMBINED LEVAMISOLE WITH RECOMBINANT INTERLEUKIN-2 (IL-2) IN PATIENTSWITH ADVANCED RENAL-CELL CARCINOMA - A PHASE-II STUDY, American journal of clinical oncology, 21(2), 1998, pp. 139-141
Authors:
BONNER JA
MCGINNIS WL
STELLA PJ
MARSCHKE RF
SLOAN JA
SHAW EG
MAILLIARD JA
CREAGAN ET
AHUJA RK
JOHNSON PA
Citation: Ja. Bonner et al., THE POSSIBLE ADVANTAGE OF HYPERFRACTIONATED THORACIC RADIOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED NONSMALL CELL LUNG-CARCINOMA - RESULTS OF A NORTH CENTRAL CANCER-TREATMENT GROUP PHASE-III STUDY, Cancer, 82(6), 1998, pp. 1037-1048
Authors:
BONNER JA
FRYTAK S
SLOAN J
FOOTE RL
MARKS RS
CREAGAN ET
RICHARDSON RL
DESCHAMPS C
Citation: Ja. Bonner et al., DAILY ETOPOSIDE AND CISPLATIN DURING THORACIC RADIOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER, International journal of radiation oncology, biology, physics, 39(2), 1997, pp. 312-312
Authors:
CREAGAN ET
ROWLAND KM
SUMAN VJ
KARDINAL CG
MARSCHKE RF
MARKS RS
MAPLES WJ
Citation: Et. Creagan et al., PHASE-II STUDY OF COMBINED LEVAMISOLE WITH RECOMBINANT INTERLEUKIN-2 IN PATIENTS WITH ADVANCED MALIGNANT-MELANOMA, American journal of clinical oncology, 20(5), 1997, pp. 490-492
Authors:
BRETSCHER ME
CREAGAN ET
Citation: Me. Bretscher et Et. Creagan, UNDERSTANDING SUFFERING - WHAT PALLIATIVE MEDICINE TEACHES US, Mayo Clinic proceedings, 72(8), 1997, pp. 785-787
Authors:
CREAGAN ET
Citation: Et. Creagan, MALIGNANT-MELANOMA - AN EMERGING AND PREVENTABLE MEDICAL CATASTROPHE, Mayo Clinic proceedings, 72(6), 1997, pp. 570-574
Authors:
CREAGAN ET
Citation: Et. Creagan, ATTITUDE AND DISPOSITION - DO THEY MAKE A DIFFERENCE IN CANCER SURVIVAL, Mayo Clinic proceedings, 72(2), 1997, pp. 160-164
Authors:
SHAW EG
FRYTAK S
EAGAN RT
RICHARDSON RL
CREAGAN ET
JETT JR
FOOTE RL
SU JQ
SCHAID DJ
LEE RE
Citation: Eg. Shaw et al., ETOPOSIDE-CISPLATIN AND THORACIC RADIATION-THERAPY SALVAGE OF INCOMPLETE RESPONDERS TO A NONCISPLATIN INDUCTION REGIMEN FOR LIMITED AND EXTENSIVE SMALL-CELL CARCINOMA OF THE LUNG, American journal of clinical oncology, 19(2), 1996, pp. 154-158
Authors:
FRYTAK S
SHAW EG
JETT JR
RICHARDSON RL
FOOTE RL
CREAGAN ET
EAGAN RT
SU JQ
Citation: S. Frytak et al., INFUSION CISPLATIN CHEMOTHERAPY AND HYPERFRACTIONATED THORACIC RADIOTHERAPY FOR SMALL-CELL LUNG-CANCER, American journal of clinical oncology, 19(2), 1996, pp. 193-198
Authors:
SCHLEUSENER JT
TAZELAAR HD
JUNG SH
CHA SS
CERA PJ
MYERS JL
CREAGAN ET
GOLDBERG RM
MARSCHKE RF
Citation: Jt. Schleusener et al., NEUROENDOCRINE DIFFERENTIATION IS AN INDEPENDENT PROGNOSTIC FACTOR INCHEMOTHERAPY-TREATED NONSMALL CELL LUNG-CARCINOMA, Cancer, 77(7), 1996, pp. 1284-1291
Authors:
CREAGAN ET
DALTON RJ
AHMANN DL
JUNG SH
MORTON RF
LANGDON RM
KUGLER J
RODRIGUE LJ
Citation: Et. Creagan et al., RANDOMIZED, SURGICAL ADJUVANT CLINICAL-TRIAL OF RECOMBINANT INTERFERON ALFA-2A IN SELECTED PATIENTS WITH MALIGNANT-MELANOMA, Journal of clinical oncology, 13(11), 1995, pp. 2776-2783
Authors:
SHAW EG
DEMING RL
CREAGAN ET
NAIR S
SU JQ
LEVITT R
STEEN PD
WIESENFELD M
MAILLIARD JA
Citation: Eg. Shaw et al., PILOT-STUDY OF HUMAN RECOMBINANT INTERFERON-GAMMA AND ACCELERATED HYPERFRACTIONATED THORACIC RADIATION-THERAPY IN PATIENTS WITH UNRESECTABLE STAGE IIIA B NONSMALL CELL LUNG-CANCER/, International journal of radiation oncology, biology, physics, 31(4), 1995, pp. 827-831
Authors:
WEISS M
LOPRINZI CL
CREAGAN ET
DALTON RJ
NOVOTNY P
OFALLON JR
Citation: M. Weiss et al., UTILITY OF FOLLOW-UP TESTS FOR DETECTING RECURRENT DISEASE IN PATIENTS WITH MALIGNANT MELANOMAS, JAMA, the journal of the American Medical Association, 274(21), 1995, pp. 1703-1705
Authors:
BONNER JA
EAGAN RT
LIENGSWANGWONG V
FRYTAK S
SHAW EG
EVANS RG
CREAGAN ET
RICHARDSON RL
Citation: Ja. Bonner et al., LONG-TERM RESULTS OF A PHASE I II STUDY OF AGGRESSIVE CHEMOTHERAPY AND SEQUENTIAL UPPER AND LOWER HEMIBODY RADIATION FOR PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG-CANCER/, Cancer, 76(3), 1995, pp. 406-412
Authors:
LIENGSWANGWONG V
BONNER JA
SHAW EG
FOOTE RL
FRYTAK S
RICHARDSON RL
CREAGAN ET
EAGAN RT
SU JQ
Citation: V. Liengswangwong et al., PROPHYLACTIC CRANIAL IRRADIATION IN LIMITED-STAGE SMALL-CELL LUNG-CANCER, Cancer, 75(6), 1995, pp. 1302-1309
Authors:
LIENGSWANGWONG V
BONNER JA
SHAW EG
FOOTE RL
FRYTAK S
EAGAN RT
JETT JR
RICHARDSON RL
CREAGAN ET
SU JQ
Citation: V. Liengswangwong et al., LIMITED-STAGE SMALL-CELL LUNG-CANCER - PATTERNS OF INTRATHORACIC RECURRENCE AND THE IMPLICATIONS FOR THORACIC RADIOTHERAPY, Journal of clinical oncology, 12(3), 1994, pp. 496-502
Authors:
CALL TG
CREAGAN ET
FRYTAK S
BUCKNER JC
VANHAELSTPISANI C
HOMBURGER HA
KATZMANN JA
Citation: Tg. Call et al., PHASE-I TRIAL OF COMBINED RECOMBINANT INTERLEUKIN-2 WITH LEVAMISOLE IN PATIENTS WITH ADVANCED MALIGNANT DISEASE, American journal of clinical oncology, 17(4), 1994, pp. 344-347
Authors:
CREAGAN ET
Citation: Et. Creagan, HOW TO BREAK BAD-NEWS - AND NOT DEVASTATE THE PATIENT, Mayo Clinic proceedings, 69(10), 1994, pp. 1015-1017
Authors:
CREAGAN ET
SCHAID DJ
HARTMANN LC
LOPRINZI CL
Citation: Et. Creagan et al., A PHASE-II STUDY OF 5,6-DIHYDRO-5-AZACYTIDINE HYDROCHLORIDE IN DISSEMINATED MALIGNANT-MELANOMA, American journal of clinical oncology, 16(3), 1993, pp. 243-244
Authors:
CREAGAN ET
Citation: Et. Creagan, STRESS AMONG MEDICAL ONCOLOGISTS - THE PHENOMENON OF BURNOUT AND A CALL TO ACTION, Mayo Clinic proceedings, 68(6), 1993, pp. 614-615
Risultati:
1-21
|